Get started
RocketTickers

SGEN Announce Positive Results from Phase 3 ECHELON-2 Clinical

Long
RocketTickers  
NASDAQ:SGEN   None
Beyond Technical Analysis
2
0
beyondta
2018-10-01 06:45:00
Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.